Sirtex profits up eightfold

By Tim Dean
Friday, 28 August, 2009

Medical device company, Sirtex, best known for its anti-cancer SIR-Spheres, has announced an impressive boost in revenues of 72 per cent over the past financial year.

In an ASX announcement, the company has indicated a 42 per cent increase in sales of its flagship product, leading to a net profit before tax of $23 million, up from $2.5 million the previous financial year.

SIR-Spheres experienced growth in all markets, up 28 per cent in the US, 117 per cent in Europe and 17 per cent in Asia Pacific.

In today's trading, Sirtex (ASX:SRX) was up 7.7% to $4.64.

Content from other channels on our network

Reading Between the Lines: A Smarter Way to Verify Allergen Safety

Machinery Regulation will be Mandatory in Less Than a Year — Are You Ready?

Swisslog's multi-temperature automation modernises cold storage and logistics

Clariant achieves EU approval for renewable additives in food-contact plastics

Opal Packaging Plus partners with Phantm to develop packaging compliance solution

$10m project to safeguard WA water supplies

Supermarket giant now powered using 100% renewables

CAWSYD26 to spotlight local climate solutions

Chip makes pH measurements easier

Adsorbents capture short-chain PFAS in water

How Floor Scrubbers Support Infection Prevention In Healthcare

The AI Revolution in Clinical Trials: New Research Reveals Why Industry Leaders Are Making the Shift Now

Hospital’s "recovery at work" collaborative approach proves a winning model

Medicine shortages are testing Australia's health system and clinicians need national support

A Day in the Life of a home support clinical care team manager

Sirtex profits up eightfold

AusBiotech and Proto Axiom partner on investor-focused life sciences programs

The University of Sydney formalises cervical cancer elimination partnership

Noxopharm says paper reveals science behind its immune system platform

Content from other channels on our network